Apexigen in licensing pact with Centocor R&D
Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.
Mereo BioPharma and Zydus Lifesciences subsidiary Sentynl Therapeutics have signed an option and licence agreement related to the US commercial and worldwide manufacturing rights to alvelestat, a potential oral treatment for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).